Adult brain tumors medical therapy: Difference between revisions
Created page with "__NOTOC__ {{Adult brain tumors}} {{CMG}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==Overview=..." |
No edit summary |
||
| Line 2: | Line 2: | ||
{{Adult brain tumors}} | {{Adult brain tumors}} | ||
{{CMG}} | {{CMG}} | ||
Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | ||
Revision as of 16:49, 18 September 2012
|
Adult brain tumors Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Adult brain tumors medical therapy On the Web |
|
American Roentgen Ray Society Images of Adult brain tumors medical therapy |
|
Risk calculators and risk factors for Adult brain tumors medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Medical Therapy
Specific genetic or chromosomal abnormalities involving deletions of 1p and 19q have been identified for a subset of oligodendroglial tumors, which have a high response rate to lomustine, procarbazine, and vincristine (PCV) therapy. Other CNS tumors are associated with characteristic patterns of altered oncogenes, altered tumor-suppressor genes, and chromosomal abnormalities. As noted above, familial tumor syndromes with defined chromosomal abnormalities are associated with gliomas. (Refer to the Classification section of this summary for more information.)